{
    "clinical_study": {
        "@rank": "95707", 
        "acronym": "FCRVADS", 
        "arm_group": {
            "arm_group_label": "Blood sample", 
            "description": "Blood sample for identifying the polymorphism"
        }, 
        "brief_summary": {
            "textblock": "Hypothesis:\n\n      Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally\n      advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive\n      biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown\n      recently that FC\u03b3RIIIA and FC\u03b3RIIA receptor polymorphisms played a role in antitumor\n      activity of trastuzumab and cetuximab.\n\n      The investigators therefore hypothesized that FC\u03b3RIIIA and FC\u03b3RIIA receptor polymorphisms\n      may play a predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers\n      with recurrence or metastatic disease that make them inaccessible to loco regional\n      treatment."
        }, 
        "brief_title": "Role of FC\u03b3RIIIA and FC\u03b3RIIA Receptor Polymorphisms", 
        "completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "condition": "Upper Gingival Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypothesis:\n\n      Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally\n      advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive\n      biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown\n      recently that FC\u03b3RIIIA and FC\u03b3RIIA receptor polymorphisms played a role in antitumor\n      activity of trastuzumab and cetuximab.\n\n      We therefore hypothesized that FC\u03b3RIIIA and FC\u03b3RIIA receptor polymorphisms may play a\n      predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers with\n      recurrence or metastatic disease that make them inaccessible to loco regional treatment.\n\n      This study is a multicentre prospective pharmacogenetic observational study, conducted on\n      locally advanced and inoperable upper aerodigestive tract cancers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with recurrent or metastatic squamous cell carcinomas of the upper\n             aero-digestive tract\n\n          -  Patient with loco-regional extension  not readily treatable\n\n          -  18 years\n\n          -  Follow up in participant center\n\n          -  Patient information and consent for study participation\n\n          -  Patient presented in multidisciplinary meeting (RCP) in Aquitaine and for whom a\n             treatment containing cetuximab has been proposed\n\n          -  Belong to a social security system\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Patient with psychological, social, family or geographical reason, who could not be\n             treated or monitored regularly by study criteria,\n\n          -  Patients deprived of liberty or under guardianship or who could not give consent for\n             study participation\n\n          -  Inclusion in another study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Squamous cell carcinomas of the upper aero-digestive tract recurrent or metastatic."
            }
        }, 
        "enrollment": {
            "#text": "121", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827956", 
            "org_study_id": "IB2009-24"
        }, 
        "intervention": {
            "arm_group_label": "Blood sample", 
            "description": "Blood sample for identifying the polymorphism", 
            "intervention_name": "Blood sample for identifying the polymorphism", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Upper aero-digestive tract tumours", 
            "FCGR3A and FCGR2A receptor polymorphism", 
            "Cetuximab efficacy"
        ], 
        "lastchanged_date": "April 9, 2013", 
        "link": {
            "description": "Site internet du promoteur, l'Institut Bergoni\u00e9", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bordeaux", 
                    "country": "France", 
                    "state": "Aquitaine", 
                    "zip": "33000"
                }, 
                "name": "Institut Bergoni\u00e9"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Role of FC\u03b3RIIIA and FC\u03b3RIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours", 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "ROBERT Jacques, PU-PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The main objective is to evaluate the role of FCGR3A and FCGR2A receptor polymorphism in cetuximab and chemotherapy response, in patients with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract", 
            "measure": "The main objective is to evaluate the role of FCGR3A and FCGR2A receptor polymorphism in cetuximab and chemotherapy response, in patients with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract", 
            "safety_issue": "No", 
            "time_frame": "Proportion of patients with positive response to treatment at 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Overall survival: defined as the time between the first cycle of chemotherapy and the date of death, all causes. In the absence of death confirmation, survival data are censored from the date of last news", 
            "measure": "Progression-free survival Overall survival  Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Progression-free survival: Tumour evaluation will be done at baseline and at 4 months or until the earlier of the following events: disease progression, patient death."
        }, 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}